TCRX Q1 2025 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+283.6% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$36M-1669.7% margin

Net Income

-$34M-1571.9% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+226.5%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$39M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$333M

Total Liabilities

$123M

Stockholders' Equity

$210M

Cash & Equivalents

$154M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$566,000	+283.6%
Gross Profit	$2M	$566,000	+283.6%
Operating Income	-$36M	-$31M	-15.5%
Net Income	-$34M	-$30M	-13.2%

Revenue Segments

Reportable Segment

$2M100%